3Sbio

3Sbio is a Chinese biopharmaceutical company known for its focus on the development of innovative therapies, particularly in the field of oncology. Recently, the company has been in the news due to a significant licensing agreement with Pfizer, which includes a $6 billion deal to develop and commercialize a promising bispecific antibody called SSGJ-707, aimed at treating various types of cancer, including non-small cell lung cancer and metastatic colorectal cancer.